Table 2. Clinical data of 11 patients with hepatitis B reactivation without antiviral prophylaxis before chemotherapy.
| Case Number | Cancer type | Department of doctor | BaselineALT (U/L) | Peak ALT (U/L) | Hepatic decompensation | HBV DNA on reactivation (IU/ml) | Courses of C/T before reactivation | Time from last C/T to reactivation (days) | Salvage treatment of reactivation | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Colon cancer | Colorectal surgery | 18 | 118 | No | 602000 | 10 | 8 | ETV 0.5mg | Recovery |
| 2 | Lung cancer | Chest medicine | 78 | 955 | No | 3950000 | 1 | 25 | ETV 0.5mg | Recovery |
| 3 | Lung cancer | Thoracic surgery | 36 | 303 | Yes | 21972 | 5 | 56 | ETV 0.5mg | Recovery |
| 4 | Colon cancer | Colorectal surgery | 31 | 121 | No | 26000 | 7 | 10 | ETV 0.5mg | Recovery |
| 5 | HCC | General surgery | 44 | 366 | No | 11853 | 2 | 39 | LdT 600mg | Recovery |
| 6 | Gastric cancer | General surgery | 29 | 880 | Yes | 4326631 | 5 | 30 | LdT 600mg | Expired |
| 7 | Lung cancer | Thoracic surgery | 30 | 217 | No | 10372 | 5 | 7 | LAM 100mg | Recovery |
| 8 | Lung cancer | Thoracic surgery | 87 | 372 | Yes | 61000 | 3 | 21 | TDF 300mg | Recovery |
| 9 | Rectal cancer | Colorectal surgery | 21 | 494 | No | > 10 10 | 4 | 17 | TDF 300mg | Recovery |
| 10 | Lung cancer | Chest medicine | 22 | 115 | No | 10126 | 2 | 8 | LAM 100mg | Recovery |
| 11 | Rectal cancer | Colorectal surgery | 18 | 468 | Yes | NA | 10 | 30 | No | Expired |
ALT, alanine aminotransferase; HCC, hepatocellular carcinoma; NA, not available; C/T, chemotherapy; ETV, entecavir; LdT, telbivudine; LAM, lamivudine; TDF, tenofovir.
All patients were hepatitis B e antigen-negative.
Case 5, Case 7, Case 10 reported themselves to be inactive HBV carriers in other medical institutions.
Case 11 died within 2 days after admission without virological data and antiviral treatment.